Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Option Exercise and Sale
SEC Form 4 Filing
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on September 3, 2024.
Summary
- On September 3, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., exercised non-qualified stock options to acquire 5,300 shares of common stock at a price of $7.96 per share.
- Simultaneously, Malik sold 2,084 shares at $56.99 and 5,300 shares at $57.02.
- Following these transactions, Malik directly owns 122,920 shares of Cytokinetics common stock and 37,100 derivative securities (non-qualified stock options).
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard Form 4 filing indicating an executive exercised stock options and sold some shares. It doesn't inherently signal positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in the number of shares outstanding.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date exercisable for Non-Qualified Stock Option (Right to Buy) |
| 02/26/2025 | Expiration date for Non-Qualified Stock Option (Right to Buy) |
| 09/03/2024 | Date of transaction: stock option exercise and sale of shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.